NICE recommends Boehringer's Vargatef

Medicines watchdog the National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending German family-owned pharma major Boehringer Ingelheim’s Vargatef (nintedanib) as an option for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer that has progressed after first-line chemotherapy.

This follows the company submitting new analyses and a patient access scheme in response to the appraisal consultation in November last year. The final draft guidance is now with consultees, who have the opportunity to appeal.